Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Highlighting the Key Takeaways From ASH 2024
June 5th 2025, 12:10pm
Unpacking Key Data from ASH 2024
Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy, bispecifics, and minimal residual disease (MRD) monitoring are reshaping lymphoma treatment strategies, with emerging data showing promising outcomes for various lymphoma subtypes and ongoing trials exploring optimal sequencing of these therapies.
Treatment and Management of MM with Amyloidosis
June 5th 2025, 12:05pm
Unpacking Key Data from ASH 2024
Panelists discuss how insights from ASH 2024 are shaping the treatment and management of multiple myeloma (MM) with amyloidosis, emphasizing early diagnosis, novel therapies, and personalized treatment strategies to improve patient outcomes.
Recommendations For Future Clinical Trials in R/R MM
June 5th 2025, 12:00pm
Unpacking Key Data from ASH 2024
Panelists discuss how insights from ASH 2024 highlight the need for personalized treatment strategies, improved trial designs, and greater inclusion of diverse patient populations in future clinical trials for relapsed/refractory multiple myeloma (R/R MM).
Trispecific Antibody JNJ-79635322 Is Safe and Demonstrates Early Efficacy Signals in R/R Myeloma
June 4th 2025, 9:05pm
JNJ-79635322 had a tolerable safety profile and elicited responses comparable with those generated by CAR T-cell therapy in relapsed/refractory myeloma.
Single-Agent Tivozanib Shows Activity in Metastatic RCC After Contemporary Frontline Therapy
June 4th 2025, 7:25pm
Tivozanib monotherapy was effective and outperformed tivozanib plus nivolumab after receipt of upfront IO/TKI or ipilimumab/nivolumab regimens in RCC.
ASCT Plus Isa-KRd Consolidation Does Not Boost MRD Negativity Rates in Myeloma
June 4th 2025, 6:05pm
ASCT added to Isa-KRd consolidation following Isa-KRd induction did not improve MRD outcomes vs continued Isa-KRd in MRD-negative, newly diagnosed myeloma.
THIO Plus Cemiplimab Shows Activity and Is Safe in ICI-Resistant Advanced NSCLC
June 4th 2025, 4:50pm
THIO plus cemiplimab showed tolerability and activity in ICI-resistant advanced NSCLC in the second- and third-line settings.
BNT327/PM8002 Plus Chemo Is Active in Unresectable Pleural and Peritoneal Mesothelioma
June 4th 2025, 4:24pm
Frontline BNT327/PM8002 plus chemotherapy was effective and safe in patients with unresectable pleural and peritoneal mesothelioma.
Fruquintinib Plus Chemotherapy and PD-1 Inhibition Is Safe and Active in Treatment-Naive HER2– Gastric/GEJ Adenocarcinoma
June 4th 2025, 12:00pm
Fruquintinib plus chemotherapy and a PD-1 inhibitor was safe and effective in patients with untreated HER2-negative advanced gastric/GEJ cancer.
NXC-201 CAR T-Cell Therapy Displays Early Activity in Relapsed/Refractory Light Chain Amyloidosis
June 3rd 2025, 10:58pm
The first CAR T-cell therapy designed for patients with relapsed/refractory AL amyloidosis showed feasibility and early efficacy and safety signals.
Dostarlimab Plus Cobolimab Improves MPR Rate vs Dostarlimab in High-Risk Resectable Melanoma
June 3rd 2025, 10:55pm
Dostarlimab plus cobolimab bested dostarlimab monotherapy in terms of MPR and RFS in patients with high-risk resectable melanoma.
Adjuvant Encorafenib/Binimetinib Is Well Tolerated and May Reduce Recurrence Risk in BRAF V600–Mutant Melanoma
June 3rd 2025, 10:50pm
Adjuvant encorafenib/binimetinib was well tolerated with a manageable toxicity profile in patients with high-risk, stage IIB/C BRAF V600-mutant melanoma.
Dr Rathkopf on the Efficacy of Niraparib Plus Abiraterone Acetate/Prednisone in HRR-Altered mCSPC
June 3rd 2025, 10:00pm
Dana E. Rathkopf, MD, discusses the efficacy of niraparib plus abiraterone acetate and prednisone in patients with mCSPC and HRR gene alterations.
Elranatamab Plus Daratumumab and Lenalidomide Is Active in Transplant-Ineligible Multiple Myeloma
June 3rd 2025, 10:00pm
Elranatamab plus daratumumab and lenalidomide was safe and effective in transplant-ineligible patients with newly diagnosed multiple myeloma.
Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer
June 3rd 2025, 9:46pm
An exploratory analysis showed a reduction in the risk of progression in locally advanced cervical cancer with undetectable ctDNA levels after treatment.
One-Third of Patients With R/R Myeloma Are Progression Free at ≥5 Years With Cilta-Cel
June 3rd 2025, 9:40pm
A single infusion of cilta-cel led to a 5-year PFS in patients with heavily pretreated relapsed/refractory myeloma in long-term follow-up of CARTITUDE-1.
Dara-KRd Boosts MRD Negativity Rates in Newly Diagnosed Multiple Myeloma
June 3rd 2025, 9:30pm
Dara-KRd improved rates of MRD negativity compared with KRd alone in patients with newly diagnosed multiple myeloma, regardless of transplant eligibility.
Olaparib Plus Radium-223 Generates Superior rPFS in CRPC
June 3rd 2025, 9:01pm
Olaparib/radium-223 demonstrated superior rPFS outcomes compared with radium-223 alone in patients with castration-resistant prostate cancer.
Perioperative IMNN-001 Plus Chemo Yields Improved Survival Trends in Newly Diagnosed Advanced Epithelial Ovarian Cancer
June 3rd 2025, 8:28pm
Perioperative IMNN-001 plus chemotherapy generated numerical survival improvements in newly diagnosed epithelial ovarian cancer.
CAN-2409 Plus EBRT Bests EBRT Alone in High-Risk Localized Prostate Cancer
June 3rd 2025, 8:10pm
CAN-2409 plus prodrug and radiation therapy significantly improved DFS vs radiation therapy alone in intermediate-to-high-risk prostate cancer.